SCHEMBL6354580

SCHEMBL6354580

NC(=O)C[C@H](NC(=O)[C@@H]1CCCN1C(=O)Cc1ccccc1)C(N)=O

nearest known ligand 0.49

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
F2 P00734 2/20 0.48
ACE P12821 2/20 0.48
OPRM1 P35372 1/20 0.47
OPRD1 P41143 1/20 0.47
OPRK1 P41145 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9140655 0.94 ACE (0.50) F2ACEOPRM1
SCHEMBL6354335 0.87 PSMB9 (0.51) F2OPRM1OPRD1OPRK1
SCHEMBL9545156 0.81 ALDH1A1 (0.51) F2
SCHEMBL6543907 0.80 CPA1 (0.51) F2ACE
SCHEMBL6354572 0.80 ACE (0.47) F2ACEOPRM1OPRD1OPRK1
SCHEMBL6352517 0.79 ITGB1 (0.55) F2
SCHEMBL18098145 0.79 F2 (0.50) F2OPRM1OPRD1OPRK1
SCHEMBL6360400 0.79 ACE (0.51) F2ACE
SCHEMBL2177077 0.78 DPP4 (0.57) ACE
SCHEMBL474918 0.78 DPP4 (0.57) ACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050222093-A1 Methods for restoring cognitive function following systemic stress PEARLMAN RODNEY 2005-10-06 US claimed
EP-1372620-A2 METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS Saegis Pharmaceuticals (US) 2004-01-02 EP claimed
US-20020187977-A1 Methods for restoring cognitive function following systemic stress SAEGIS PHARMACEUTICALS, INC. 2002-12-12 US claimed
WO-2002074293-A2 METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS SAEGIS PHARMACEUTICALS INC (US) 2002-09-26 WO claimed
US-20050222093-A1 Methods for restoring cognitive function following systemic stress PEARLMAN RODNEY 2005-10-06 US disclosed
EP-1372620-A2 METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS Saegis Pharmaceuticals (US) 2004-01-02 EP disclosed
US-20020187977-A1 Methods for restoring cognitive function following systemic stress SAEGIS PHARMACEUTICALS, INC. 2002-12-12 US disclosed
WO-2002074293-A2 METHODS FOR RESTORING COGNITIVE FUNCTION FOLLOWING SYSTEMIC STRESS SAEGIS PHARMACEUTICALS INC (US) 2002-09-26 WO disclosed
US-5439930-A Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects RUSSIAN-AMERICAN INSTITUTE FOR NEW DRUG DEVELOPMENT (US) 1995-08-08 US disclosed
WO-1993021216-A1 BIOLOGICALLY ACTIVE N-ACYLPROLYLDIPEPTIDES HAVING ANTIAMNESTIC, ANTIHYPOXIC AND ANOREXIGENIC EFFECTS RUSSIAN-AMERICAN INSTITUTE FOR NEW DRUG DEVELOPMENT (US) 1993-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222093-A1 Methods for restoring cognitive function following systemic stress CRH, BDNF, CHAT F2 2778/4885ACE 97/4885OPRM1 3400/4885
US-20020187977-A1 Methods for restoring cognitive function following systemic stress CRH, BDNF, CHAT F2 2778/4885ACE 97/4885OPRM1 3400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.